(OTCBB: LGDI), (OTCPK: LLBT), (OTC.BB: IFLI), (OTCBB: SYBD), (OTCBB: XDRC), (PINKSHEETS: FFGO).

RealPennies.com: Turning Pennies into dollars: (OTCBB: LGDI), (OTCPK: LLBT), (OTC.BB: IFLI), (OTCBB: SYBD), (OTCBB: XDRC), (PINKSHEETS: FFGO).

Are you a public company looking for exposure?
Contact RealPennies.com - 1.800.940.6559

For more info: http://llbt.realpennies.com

Lifeline Biotechnologies, Inc. (OTCPK: LLBT)(December 18, 2007) announced earlier today that the Company has recently provided patient cases to Nanyang Technical University to aid in the development of the First Warning System's (FWS) interpretive analytical system. One objective is to make it more user friendly for women to assist in the detection of breast cancer.

Originally, the FWS was worn by women for 48 hours, with eight sensors on each breast. This length of time caused issues because the longer the testing period, the more the likelihood women would accidentally loosen a sensor and send faulty data. After analyzing the patient cases, Lifeline, along with the work at Nanyang Technical University, has been working to reduce the testing period to 24 hours or less, which will make it more user friendly for women and increase the accuracy of the FWS.

"We believe that shortening the time that women have to wear the device will provide more comfort and not interrupt their daily activities. Our enhancements to the software will enable us to cut down the testing time in half, possibly less, and make the detection of breast cancer an easier process," stated Jim Holmes, CEO of Lifeline Biotechnologies, Inc.

Lifeline Biotechnologies is in the process of securing FDA clearance, via a 510(k) for its First Warning System, and will continue to update its shareholders regarding its progress on a regular basis.

Lifeline Biotechnologies, Inc. is an innovative medical technology company that is focused on completing the development of the First Warning System, which was designed to assist in the early detection of breast cancer. Of the approximately $138 billion spent on cancer each year, Lifeline could potentially save the healthcare industry up to $4.1 billion annually, assuming the following are successfully completed: the development of the First Warning System, the completion of clinical trials and FDA pre-marketing clearance. Lifeline competes in the money markets for funds to support the development of its product. The cost of funds, for early stage companies like Lifeline, are expensive and the terms have been, and may continue to be, dilutive.

For more info: http://ifli.realpennies.com

The International Fight League (OTC.BB: IFLI) (December 17, 2007)and Alfred Haber Distribution (AHDI) announced earlier today that HBO Latin America, one of the fastest growing entertainment channels in Latin America will begin showing IFL content beginning in 2008. It is the IFL's first Spanish Language partnership, and will cover Latin America, Brazil and the Caribbean.

"Serving one of the fastest growing demos for Mixed Martial Arts, the Hispanic market both in the United States and abroad, is a major priority for the IFL in 2008," said IFL CEO Jay Larkin. "We are very pleased to be able to start that progress with one of the hallmark brands in all of broadcasting, HBO, and its Latin American arm." HBO Latin America joins an ever-growing international TV lineup for IFL programming, which includes MyNetworkTV, HDNet and FSN in the United States, MBC in the Middle East and parts of Africa, Star TV in Asia, CanWest Global and Fox Sports Canada in Canada, EGO in Israel, ITV in the United Kingdom, TV4 in Sweden and Armed Forces Television worldwide.

Just completing its first full season of operation, IFL programming will now be seen in over 300 million homes worldwide.

HBO Latin America Group(SM) is composed of affiliates of Time Warner Entertainment Company, L.P., Sony Pictures Entertainment, Inc., The Walt Disney Company and Ole Communications Group. The HBO Latin America Group(SM) of companies own, operate and distribute the leading cable and satellite programming services in Latin America, Brazil and the Caribbean, including HBO , HBO Plus , Cinemax , Cinemax Prime, E! Entertainment Television, A&E Mundo, The History Channel, Sony Entertainment Television and Warner Channel. HBO Latin America Group(SM) also distributes The Disney Channel and AXN in Latin America.

For more info: http://sybd.realpennies.com

Synthetic Blood International, Inc. (OTCBB: SYBD)(December 18, 2007) announced earlier today its near-term development strategy for Oxycyte. The Company finalized its Phase IIb Oxycyte clinical trial protocol for the treatment of traumatic brain injury (TBI), and plans to initiate three pre-clinical animal studies in sickle cell disease, spinal cord injury and stroke in the first half of 2008. Oxycyte is the Company's proprietary perfluorocarbon (PFC) therapeutic oxygen carrier and blood substitute.

These Oxycyte development initiatives were determined at the Company's Scientific Advisory Board (SAB) meeting conducted last week. Synthetic Blood also announced its intention to invite six to eight physicians to join the SAB in a move to broaden its specialties. The SAB candidates are expected to be primarily located at medical centers that may be involved with Oxycyte trials.

"We have taken a major step toward FDA submission of a Phase IIb protocol in TBI," said Robert Larsen, Interim President and CEO of Synthetic Blood. "Further, favorable data from our Phase IIa pilot clinical study in TBI demonstrated Oxycyte's ability to provide oxygen transport to tissues immediately after injury. Based on these and other study data, we believe that Oxycyte could significantly reduce permanent damage and improve recovery outcomes in additional indications." Bruce Spiess, M.D., Virginia Commonwealth University Professor and Vice-Chairman of Anesthesiology, Chief of Cardiothoracic Anesthesia and Director of the Research Department of Anesthesiology, and Synthetic Blood's SAB Chairman, stated, "We plan to study the effects of repeat dosing with Oxycyte, which could provide additional clinical benefits. The time course of brain improved oxygenation occurs immediately after Oxycyte administration and lasts for approximately 18 to 24 hours. However, the potential for neuronal death can continue for as long as seven to 10 days after initial injury. Repeat dosing, if safe without any adverse side effects, could greatly increase the oxygenation of the tissue involved." Previous animal studies have indicated that early intervention with Oxycyte helps to prevent the destruction of nerve cells in spinal cord injuries and provides oxygen to brain tissues in stroke.

Sickle cell disease is a genetic condition caused by abnormal hemoglobin that crystallizes under low oxygen concentrations. This change leads to cells becoming misshapen and unable to move through the microcirculation. Sickle cell disease currently affects an estimated 100,000 people in the United States, as many as 50 million people in the African sub-Sahara, as well as large populations in India.

Stroke is the third leading cause of death in the U.S. and accounts for more than 162,000 deaths in the U.S. each year. According to the American Heart Association, 700,000 Americans each year experience a new or recurrent stroke. Stroke is the number one cause of long-term disability among Americans.

Spinal Cord Injury is damage to the spinal cord that results in a loss of function such as mobility or feeling and can result in paralysis. Spinal cord injury affects approximately 250,000 individuals in the U.S., increasing at a rate of approximately 11,000 new cases per year.

Synthetic Blood International is dedicated to commercializing innovative pharmaceuticals and medical devices in the field of oxygen therapeutics and continuous substrate monitoring. The Company has under development a blood substitute and a liquid ventilation product, and an implantable glucose sensor. These products are based upon core technologies that include biomedical applications for PFCs, and medical and industrial applications for biosensors. Each of the product candidates is designed with advantages over currently marketed products in major markets including acute respiratory distress syndrome, stroke, myocardial infarction, surgery, trauma, malignant tumors and diabetes. For further information, visit www.sybd.com.

For more info: http://ffgo.realpennies.com

Fortress Financial Group, Inc. (PINKSHEETS: FFGO)(December 18, 2007) confirmed earlier today that the Transfer Agent to Hunt Gold Corporation (PINKSHEETS: HGLC) has now commenced the process of issuing Hunt Gold Corporation shares of Common Stock to all stockholders of Sentinel Resource Holdings plc, Ambassador Gold Holdings plc and Golden Eagle Mining Holdings plc The amount of 407,250,000 shares of Hunt Gold Corporation Common Stock, representing 41% of the outstanding shares in Hunt Gold Corporation are being issued, by the Transfer Agent to Hunt Gold Corporation; to Fortress Financial Group, Inc. (formerly Great West Gold, Inc.) eligible stockholders.

Stockholders may request information on their stockholdings in Hunt Gold Corporation, in writing, to :- Action Stock Transfer Corp 7069 S. Highland Drive Suite 300 Salt Lake City UT 84121 Fax : (801) 274-1099 All stockholders are being advised in writing, as to the amount of their stockholdings in Hunt Gold Corporation. Eligible stockholders may request their Stock certificates in Hunt Gold Corporation from the Transfer Agent.

The Company is aware that many stockholders, who were eligible for these Stock Dividends, hold their shares in the brokerage accounts, through "Cede & Co.". We are addressing this issue with the Transfer Agent to Hunt Gold Corporation to ensure that these stockholders are identified and issued their stock in Hunt Gold Corporation without delay.

Fortress Financial Group, Inc. has received an amount of 483,750,099 shares of Hunt Gold Corporation Common Stock, representing 48% of the outstanding stock in Hunt Gold Corporation.

Fortress Financial Group, Inc. does not intend to retain all of its stock in Hunt Gold Corporation and intends to distribute the majority of its stockholding in that Company, to Fortress Financial Group, Inc. stockholders, as a special Stock Dividend, in the near future. Stockholders will be advised accordingly. The current Board of Directors, of Hunt Gold Corporation, has resigned with immediate effect. As announced, we have appointed our representatives, on an interim basis, to constitute the Board of Directors of Hunt Gold Corporation. This to implement and complete all "Non Mining" and "Corporate" transactions required in and during this month, being the transition period for Hunt Gold Corporation. Mr Peter J Bezzano, the Chairman for Fortress Financial Group, Inc. has assumed the role of Chairman of Hunt Gold Corporation, in the interim.

Peter J Bezzano, the Chairman of Fortress Financial Group, Inc. commented that "he was delighted that the Company was making good on its promises to its stockholders and that this transaction with Hunt Gold Corporation was only the beginning of our stated process of unlocking value for our stockholders. He added that the US$600 million in Hunt Gold Corporation shares of Common Stock was now being distributed to our loyal and long standing stockholders; with the Company retaining a further amount of US$750 million (equating to a value of US$0.17 per share of Fortress Financial Group, Inc. Common Stock, post today's 25% Stock Dividend) in Hunt Gold Corporation shares of Common Stock, much of that stockholding to be distributed to our stockholders in the near future." Fortress Financial Group, Inc. continues to hold the majority interest in the "Bouse" and "South Copperstone" Gold Mining Exploration properties and expects to dispose of these interests, shortly, to a quoted Gold Mining & Exploration Company. Stockholders will be briefed, shortly, in respect of this transaction. This is an unrelated transaction to that of Hunt Gold Corporation.

Fortress Financial Group, Inc. (formerly Great West Gold, Inc.), was a gold mining exploration stage company, engaged in the acquisition and exploration of mining properties in the United States. The Company retained these Gold Mining Exploration interests as portfolio assets; as it intended to extract value from these assets through a future "spin off" or a sale. The Company has disposed of its interests in the "Ambassador", "Golden Eagle" and "Mockingbird" Gold Mining Exploration properties to Hunt Gold Corporation (PINKSHEETS : HGLC); and holds approximately 48% of Hunt Gold Corporation shares of outstanding Common Stock, as an investment.

Read our full disclaimer at: http://www.realpennies.com/start.html

Investors are advised that this analysis is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy. This report does not have regard to the specific investment objectives, financial situation and the particular needs of any specific person who may receive this information. The information contained herein is based on sources that we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. Past performance is no guarantee of future results. Please consult a broker before purchasing or selling any securities mentioned on RealPennies. For more movers: http://www.realpennies.com/wrapup.html

Any opinions expressed herein are statements of our judgment as of the date of publication and are subject to change without notice.
Sitemap: http://www.realpennies.com/sitemap.html

RealPennies .

Telephone: 1-800-940-6559

Matt /at/ realpennies.com